Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2025)

Beta Bionics (BBNX) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $328.7 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 119.68% to $328.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 786.62% year-over-year, with the annual reading at $328.7 million for FY2025, 119.68% up from the prior year.
  • Liabilities and Shareholders Equity hit $328.7 million in Q4 2025 for Beta Bionics, roughly flat from $330.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $338.0 million in Q1 2025 to a low of $110.0 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $264.4 million across 3 years, with a median of $329.4 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 35.99% in 2024 and later soared 119.68% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $110.0 million in 2023, then surged by 35.99% to $149.6 million in 2024, then skyrocketed by 119.68% to $328.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BBNX at $328.7 million in Q4 2025, $330.0 million in Q3 2025, and $330.0 million in Q2 2025.